Baxter Wins Conditional Approval From EU to Buy Gambro

Baxter International Inc. (BAX), the world’s second-largest maker of dialysis products, won conditional approval from European Union to buy Swedish competitor Gambro AB to expand its kidney-equipment business.

To allay competition issues, Baxter agreed to divest its continuous renal replacement therapy (CRRT) business, which serves patients suffering from acute kidney failure, the European Commission said in an e-mailed statement today.

To contact the reporter on this story: Gaspard Sebag in Brussels at

To contact the editor responsible for this story: Peter Chapman at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.